Sandoz Set To Become Public Company In 2023 As Novartis Confirms Spin-Off
No Formal Offers Received For Sandoz To Date But Novartis Would Have To Consider
Following years of dedicated moves towards greater autonomy for Sandoz, the generics and biosimilars giant is to become a publicly traded, standalone firm via a 100% spin-off from parent Novartis. However, a substantial offer could still derail plans.
